依达拉奉联合rh-EPO改善ACI静脉溶栓缺血-再灌注损伤的效果观察

The Effect of Edaravone Combined with rh-EPO on the Improvement of the Myocardial Ischemia-Reperfusion Injury in Patients with ACI

目的:观察依达拉奉联合重组人促红细胞生成素(rh-EPO)改善急性脑梗死(ACI)静脉溶栓缺血-再灌注损伤的效果。方法:将我院收治的68例符合静脉溶栓指标的ACI患者随机分为对照组(n=34,静脉溶栓+依达拉奉治疗)与观察组(n=34,静脉溶栓+依达拉奉+rh-EPO治疗),观察两组患者美国国立卫生院神经功能缺损量表(NIHSS)评分、日常生活能力评分(ADL)、血生化指标差异及不良反应情况。结果:治疗后,两组NIHSS水平显著降低(P<0.05),ADL评分显著提高(P<0.05),且观察组变化幅度更大(P<0.05);治疗后,两组血生化指标中血清超氧化物歧化酶(SOD)水平显著提高(P<0.05),丙二醛(MDA)、神经元特异性烯醇化酶(NSE)与血浆内皮素(ET)水平显著降低(P<0.05),且观察组变化幅度更大(P<0.05);两组治疗过程中的不良反应发生率差异无统计学意义(P>0.05)。结论:依达拉奉联合rh-EPO可显著改善ACI静脉溶栓患者的神经功能,提高日生生活能力,还可改善缺血-再灌注损伤情况。

Objective: To observe the effect of Edaravone combined with recombinant human erythropoietin (rh-EPO) on the treatment of acute cerebral infarction (ACI) venous thrombolysis ischemia-reperfusion injury. Methods: 68 patients with ACI in our hospital were randomly divided into control group (n=34, intravenous thrombolysis + Edaravone treatment) and observation group (n=34, intravenous thrombolysis + Edaravone + rh-EPO). The neurological deficit scale (NHSS) score, daily life ability score (ADL), blood biochemical index difference and adverse reaction condition of the two groups were observed. Results: After treatment, the level of NIHSS in the two groups decreased significantly (P<0.05), the ADL score in the observation group increased significantly (P<0.05), and the extent of change in the observation group was greater (P<0.05). After treatment, the levels of serum superoxide dismutase (SOD), malondialdehyde (MDA), neuron-specific enolase (NSE) and plasma endothelin-(ET)(et-(ET) were significantly increased in the two groups (P<0.05). Moreover, the range of changes in the observation group was greater (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05). Conclusion: Edaravone combined with rh-EPO can significantly improve the neurological function of patients with ACI, improve the daily life and improve the ischemia-reperfusion injury.